Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTORA vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 2–4 hours in adults, but can range from 2 to 6 hours depending on hepatic clearance. In elderly or hepatically impaired patients, half-life may be prolonged. The rapid initial decline is due to redistribution, and the terminal phase reflects slow elimination from deep compartments.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
FENTORA is primarily metabolized by CYP3A4 to norfentanyl and other metabolites.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal: Approximately 75% of the dose is excreted in urine as metabolites (mostly norfentanyl, despropionylfentanyl, and hydroxyfentanyl), with less than 7% as unchanged fentanyl. Fecal elimination accounts for about 9%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 80–85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein (AAG). Binding is concentration-dependent and may decrease in conditions with low albumin or elevated AAG.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution (Vd) is 3–6 L/kg, indicating extensive tissue distribution. Large Vd reflects high lipophilicity and rapid uptake into tissues such as fat and muscle, contributing to redistribution and prolonged effects with repeated doses.
4-6 L/kg; large Vd indicates extensive tissue distribution
Buccal administration: Absolute bioavailability is approximately 65–70% due to first-pass metabolism and some swallowed drug. Sublingual delivery is similar, but variability is high. Compared to IV, buccal bioavailability is consistent at ~65%.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For GFR <30 m L/min: initiate at 50 mcg (half a 100 mcg tablet) and titrate cautiously; no specific adjustment for GFR 30-89 m L/min.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A or B: initiate at 50 mcg and titrate cautiously; Child-Pugh Class C: not recommended.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for use in pediatric patients (safety and efficacy not established).
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at 50 mcg in patients aged ≥65 years and titrate cautiously; monitor for respiratory depression and cognitive impairment.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; RISK OF SEROTONIN SYNDROME; RISK OF ADRENAL INSUFFICIENCY; SEVERE HYPOTENSION; GASTROINTESTINAL ADVERSE REACTIONS; SEIZURES; AND INCREASED INTRACRANIAL PRESSURE, HEAD INJURY, OR IMPAIRED CONSCIOUSNESS.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Life-threatening respiratory depression,Addiction, abuse, and misuse,Risk of medication errors (dosing and product confusion),Accidental exposure (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Risk of serotonin syndrome,Risk of adrenal insufficiency,Severe hypotension,Gastrointestinal adverse reactions (e.g., constipation),Seizures,Increased intracranial pressure,Use in patients with head injury or impaired consciousness
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Opioid non-tolerant patients,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Known hypersensitivity to fentanyl or any components of FENTORA
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit juice and grapefruit products as they inhibit CYP3A4 and can increase fentanyl levels, raising risk of respiratory depression and QT prolongation. Do not consume alcohol; additive CNS depression may occur. No other known significant food interactions; however, avoid high-fat meals immediately before or after administration as they may alter absorption.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Insufficient human data; animal studies show increased skeletal anomalies and reduced fetal weight at high doses. Fentanyl is not a major teratogen but chronic use may cause neonatal opioid withdrawal syndrome (NOWS) in third trimester. Avoid in pregnancy unless benefits outweigh risks.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fentanyl is excreted in breast milk; M/P ratio not established but assumed similar to parenteral fentanyl (M/P ~0.5-1). Effect on infant minimal with single use, but chronic use may lead to opioid exposure. Use caution and monitor infant for sedation and respiratory depression.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustments for fentanyl in pregnancy; pharmacokinetic changes may require higher doses due to increased clearance and volume of distribution. Use lowest effective dose and titrate to effect.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
FENTORA (fentanyl buccal tablet) is an immediate-release opioid indicated only for breakthrough pain in opioid-tolerant cancer patients. Do not use in opioid-naive patients due to risk of fatal respiratory depression. The tablet must not be split, crushed, or chewed; place in buccal cavity. Onset of analgesia occurs within 15 minutes. Due to QT prolongation risk, avoid use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) and in patients with electrolyte abnormalities. Follow single-tablet administration and wait at least 2 hours before treating another episode. Tear the blister pack before placing; do not store opened blister.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Use only for breakthrough pain if you are already taking around-the-clock opioid medication and are tolerant to it.,Do not use this medicine if you have not taken opioids before; it can cause life-threatening breathing problems.,Place the entire tablet in your cheek pouch above a back molar; do not crush, chew, or swallow it.,Allow tablet to dissolve completely; do not eat or drink until it has fully dissolved (about 14–25 minutes).,If you get more than one breakthrough pain episode per day, contact your doctor; do not increase the dose on your own.,Store in original sealed blister pack; keep out of reach of children and dispose of unused tablets properly.,Avoid alcohol and grapefruit juice while using this medicine.,Do not drive or operate machinery until you know how this medicine affects you.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTORA vs ABSTRAL, answered by our medical review team.
FENTORA is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTORA and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTORA is: For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENTORA and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENTORA is classified as Category C. Insufficient human data; animal studies show increased skeletal anomalies and reduced fetal weight at high doses. Fentanyl is not a major teratogen but chronic use may cause neonat. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.